anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Implantable cardiac monitor (ICM) is an invaluable tool for diagnosing cardiac arrhythmia (1). Cryptogenic stroke, unexplained syncope and arrhythmia diagnosis are the most common indication for long term cardiac monitoring device. (2, 3). Reveal LINQTM (Medtronic, Inc.) is widely used for all of these purposes in the country. We have previously reported the use of Reveal XT in the use of atrial fibrillation (AF) surveillance in patient's post-AF ablation (2). We indicated that ICM is useful in long term monitoring of atrial arrhythmia in patients at risk of atrial fibrillation. Crystal AF (4) study also showed the importance of using ICM in detecting occult AF in patients with cryptogenic stroke in a timely manner so that appropriate treatment can be prescribed. The key to the success of ICM rest on how timely and reliable the ICM data can be transmitted to physician's office immediately after an arrhythmic events so the data can be analyzed and treatment rendered. Reveal LINQTM data transmission consists of two steps: 1. Data needs to be download into the MyCareLink™ monitor (scheduled daily at 2 am in the morning and monitor needs to be in the within 6 feet proximity of the patient) 2. MyCareLink™ monitor to be connected to the 3 G cellular network for the data transmission. (Fig 1). In cases of patient activated events, data transmission utilizes similar pathway.

We have reported significant delay in data transmission in the Reveal LINQTM occurs frequently and failure to connect among the Reveal LINQTM, MyCareLink™ monitor and the cellular network is the main reason for data transmission disruption and critical data could be concealed for an extended periods. To illustrate the importance of timely transmission of patient data, a Reveal LINQTM was implanted in a 54-year-old gentle man with past medical history of recurrent syncope. On 8/12/2017 the patient developed new onset dizziness and 6 seconds sinus pause was recorded by the device. However, a connection problem of MyCarelinkTM system made data unavailable until next scheduled office visit on 11/15/2017. The physician was notified on the same day and a pacemaker was implanted on the following day, almost 3 months after his significant arrhythmic events.

The newer generation of ICM such as Confirm Rx™ (Abbott, Inc) is connected directly to a patient's existing smartphone using the Bluetooth technology. By allowing patients to record and transmit symptoms with the mobile app, Confirm Rx™ ICM brings continuous remote monitoring to patients without the need for a home-based monitor (Fig 2). It is unclear which technologies offers faster and more reliable transmission of critical patient information to physician office so timely treatment can be provided. We therefore propose a pilot randomized study comparing Confirm Rx™ and Reveal LINQTM in the reliability and timeliness in data transmission.
PURPOSE: A cosmetic composition in which color is instantly changed by physical mixing is provided to effectively stabilize an active ingredient, to visualize expiration date of a cosmetic product, and to enhance reliability and preference. CONSTITUTION: A double layer cosmetic composition in which color is instantly changed by physical mixing comprises an aqueous phase of a lower layer and an oil phase of an upper layer. The cosmetic composition contains a water-soluble active material core and a capsule. The capsule surrounds the core and is formed in a shell containing an oxygen-sensitive indicator and a coat material. A method for preparing the cosmetic composition comprises: a step of providing a capsule of a core-shell structure; a step of mixing the capsule, a water-soluble active material, and reducing sugar to prepare an aqueous phase; and a step of adding the oil phase to the aqueous phase. [Reference numerals] (AA) Oil phase part; (BB) Water phase part; (CC) Mix; (DD) Maintain; (EE) Oxygen; (FF) Capsule; (GG) Shell (Indicator + Film material); (HH) Active component (Core)
Baclofen USP is a muscle relaxant and antispastic.

Its chemical name is 4-amino-3-(-4-chlorophenyl)-butanoic acid. The structural formula is:

Baclofen USP is a white to off-white, odorless or practically odorless crystalline powder. It is slightly soluble in water, very slightly soluble in methanol and insoluble in chloroform.

Each tablet, for oral administration, contains 10 mg or 20 mg baclofen. In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, pregelatinized starch, colloidal silicon dioxide, and magnesium stearate.
PURPOSE: A transition metal oxide/tantalum oxide core/shell nanoparticle is provided to be used as an X-ray CT contrast agent and an MRI T2 contrast agent by combining a biocompatible molecule or ligand on the surface of a tantalum oxide shell. CONSTITUTION: A core/shell nanoparticle comprises a transition metal oxide core and a tantalum oxide shell. The transition metal oxide is selected from ferric oxide, manganese oxide, ceria, titanium oxide, nickel oxide, cobalt oxide, and zinc oxide. The size of the transition metal oxide is 1-100 nm, and the thickness of the tantalum oxide shell is 1-50 nm. A silane group or a phosphine group is combined to the surface of the tantalum oxide shell, and a functional material is combined to the silane group or the phosphine group. The functional material is selected from a biocompatible material, organic dye, a bioactive material, a functional group, an organic molecule, organic metal, a nanoparticle, a shell structure, or a combination thereof.
Disclosed is a formulation treating joint ache, said formulation comprising oral formulation and external heat treatment components. The oral formulation components are as follows, by gram: 1-10 grams of poria, 1-10 grams of radix astragali, 1-10 grams of fructus schisandrae, 1-10 grams of radix codonopsis, 5-15 grams of sheep bone, 5-20 grams of ox marrow, 1-15 grams of bulbus allii macrostemi, 1-10 grams of fructus aurantii, 1-15 grams of semen persicae, 1-15 grams of panax notoginseng, 1-5 grams of folium ginkgo, 1-15 grams of radix aucklandiae, 5-15 grams of retinervus luffae fructus, 1-10 grams of flos carthami, 1-15 grams of herba abri, 1-15 grams of caulis spatholobi, and 1-15 grams of herba plantaginis. The external heat treatment components are as follows, by gram: 5-25 grams of rhizoma atractylodis, 5-15 grams of caulis spatholobi, 1-20 grams of semen strychni, 5-15 grams of herba plantaginis, 5-10 grams of ginger, 5-10 grams of pericarpium citri reticulatae, and 5-10 grams of radix bupleuri. The formulation treating joint ache uses oral and external local heat treatment means for internal and external administration, improving a treatment effect. The oral formulation components ease pain at the affected area. The formulation uses supplementation means to treat qi and blood stagnation and blood stasis and coagulation, improves immunity and metabolism, and reduces the possibility of relapse.
The primary objective is to determine the effect of tHGNS on tongue position in the upper airway in subjects undergoing an EP, cardiac catheterization or device procedure. (Measured as changes in the anteroposterior dimensions (2-dimensional) of the retropalatal and retrolingual airway spaces.) This will be an acute study lasting no more than 45 min during a standard new device implant, cardiac catheterization and/or EP procedure. The hypoglossal nerve will be stimulated from the lingual vein using various stimulation parameters. Tongue motion, upper airway opening or any side effects will be recorded. At the end of the test procedure all hardware - the catheters, lead and/or guide wire will be removed.
The invention discloses a gargle for relieving thirsty symptom and a preparation method thereof. The active ingredient of the gargle comprises a linseed extract and chitosan and further comprises inorganic salt, preservative and water. The preparation method comprises the following steps of: firstly, acquiring water-soluble linseed extract; secondly, adding the components to water, stirring and dissolving at room temperature; filtering and removing impurities and finally fixing the volume to obtain the product. The invention has the features of reducing chronic and transient thirsty symptoms resulting from the situations such as diseases, taking medicine, radiotherapy and chemotherapy or aging and the like; soft and hard tissues in the oral cavity can be lubricated and wetted to relieve the thirsty symptom of a patient with thirsty symptom. Because the product has good water binding ability, the time of keeping the oral cavity wet can be prolonged and the pain, caused by the thirsty, of the patient can be eased; meanwhile, the oral cavity can be cleaned and the halitosis can be prevented. The invention has the advantages of remarkable curative effect, simple preparation method and low cost and the like; and the gargle for relieving thirsty symptom can be used as medicine for treating thirsty symptom.
Nucleotide-binding domain and leucine-rich repeat-containing receptor (NLR) proteins can form complex receptor networks to confer innate immunity. An NLR-REQUIRED FOR CELL DEATH (NRC) is a phylogenetically related node that functions downstream of a massively expanded network of disease resistance proteins that protect against multiple plant pathogens. In this study, we used phylogenomic methods to reconstruct the macroevolution of the NRC family. One of the NRCs, termed NRC0, is the only family member shared across asterid plants, leading us to investigate its evolutionary history and genetic organization. In several asterid species, NRC0 is genetically clustered with other NLRs that are phylogenetically related to NRC-dependent disease resistance genes. This prompted us to hypothesize that the ancestral state of the NRC network is an NLR helper-sensor gene cluster that was present early during asterid evolution. We provide support for this hypothesis by demonstrating that NRC0 is essential for the hypersensitive cell death that is induced by its genetically linked sensor NLR partners in 4 divergent asterid species: tomato (Solanum lycopersicum), wild sweet potato (Ipomoea trifida), coffee (Coffea canephora), and carrot (Daucus carota). In addition, activation of a sensor NLR leads to higher-order complex formation of its genetically linked NRC0, similar to other NRCs. Our findings map out contrasting evolutionary dynamics in the macroevolution of the NRC network over the last 125 million years, from a functionally conserved NLR gene cluster to a massive genetically dispersed network.
Patients should be counseled that antibacterial drugs, including FORTAZ, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When FORTAZ is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by FORTAZ or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible.
The invention discloses a medical data ownership management method, which comprises following steps. Granting a first authority to a medical unit by an administrator unit, where the first authority allows the medical unit to generate a first medical object with its corresponding first non-fungible token (NFT) storing on a blockchain. Granting a second authority to a research unit by the medical unit, where the second authority allows the research unit to access the first medical object, and the research unit processes the first medical object to generate the second medical object with its corresponding second NFT storing on the blockchain. Finally, granting a third authority to a user unit by the research unit, where the third authority allows the user unit to access the second medical object. The access control and ownership transfer of each medial object in the blockchain are achieved by trading the corresponding NFT and modifying its relationship table. With the management method, the security and the privacy of the medical data will be enhanced.
There is provided compositions and methods to inhibit the adherence of pathogenic microorganisms to cells. The composition includes water soluble PEO/PEG polymers which may be hydrophilic or amphiphilic block copolymers. One example of a suitable composition is polyethylene glycol or polyethylene oxide with a chemical formula of H-(OCH2CH2)n-OH. Another example of a suitable composition is amphiphilic block copolymer with a chemical formula PEOm-Xp-PEOn, where PEO is -(OCH2CH2)n-O and X is PPO(-(OCH2 CH2CH2)m-), or PLGA (poly(lactic-co-glycolic acid), or PMMA (polymethyl methacrylate), or PBO (polybutylene oxide). The pathogenic microorganism may be a bacterial, fungal, viral or trichomonial pathogen and the composition prevents adherence of the pathogenic microorganism in, for example, a urogenital tract of a mammal and aids in reducing malodor generation. The composition may be applied to vaginal health products like, for example, moisturizer, gel, jelly, cream, insert (tablet), ointment, foam. The composition may also be applied to a feminine hygiene product, like, for example, a tampon, feminine pad, feminine wipe or panty liners.
Capsules use 1 cap for every 10 kg of body weight.A total of 6 cap under 60 kg a day, an extra 1cap for each additional 10 kg over 60 kg. Use from the 7th day of the 2nd course of treatment for 5 months.
Fibrosis is a pathological manifestation in which connective tissue replaces normal one. It can affect many tissues from the skin to internal organs such as the lungs. Manifestations of pulmonary involvement can be pulmonary arterial hypertension or pulmonary fibrosis. The latter one is currently the leading cause of death in various autoimmune diseases, including systemic sclerosis. Our study group consists of 50 patients with systemic sclerosis: 24 with limited cutaneous form and 26 with diffuse cutaneous form. This cohort was compared to 50 healthy controls (age and sex matched); our aim is to explore the distribution of TH17 cells (TH17) as well as regulatory T cells (TREG) and study their correlation with the disease's progress. Our results show an increase for IL17A in patients compared to controls and that this increase is correlated with a specific clinical involvement: Pulmonary fibrosis. This correlation suggests a crucial role of IL17A in fibrosis especially in systemic sclerosis. In addition, we have shown that the percentages of TH17 cells are higher in patients; however, the percentages of TREG cells are similar between patients and controls. A study of TREG cell activity showed that TREG lost suppressive activity by inactivating the FOXP3 transcription factor. This proves that despite their presence, TREG does not adequately carry out their regulatory activity. Finally, we analyzed the correlation between TH17/TREG and clinical damage; the results show a positive correlation with pulmonary involvement proving the role of TH17/TREG balance in induced fibrosis in systemic sclerosis. No significative difference was observed, for all the parameters, between the two different forms of the disease. In conclusion, the results associated with the TH17/TREG scale and their correlations with fibrosis in systemic sclerosis open a way for new tools to manage this autoimmune disease, which up to today has neither treatment nor accurate diagnosis.
After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin \> 12g/dL.
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Beginning 6 weeks after surgery, patients with residual disease undergo standard of care radiation therapy and receive atezolizumab IV over 30-60 minutes on day 1. Treatment with atezolizumab repeats every 21 days for up to 15 cycles in the absence of disease progression and unacceptable toxicity.
Tension-type headache is treated by interacting with neuronal transmission in relation to pain in connection with headache in a way which prevents or decreases sensitization of second order nociceptive neurons. In particular, treatment is performed by administration of an effective amount of a substance which prevents or decreases central sensitization. Important examples of such substances are substances which interact with glutamate neurotransmission, such as glutamate receptor antagonists, such as NMDA receptor antagonists, such as MK-801 or Amitriptylline or Imipramine or Desipramine or Mirtazaprine or Venlafaxine. Other examples are substances which interact with nitric oxide, such as nitric oxide synthase (NOS) inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA. According to a broader aspect of the invention tension-type headache is treated by administration of substances which are effective in preventing or decreasing pain in connection with tension-type headache, such as the substances mentioned above. An additional aspect of the invention relates to treatment of tension-type headache by administration of substances which substantially inhibit the activity of nitric oxide synthase (NOS), such as NOS inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA.
Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
BACKGROUND: Minimally invasive surgical techniques for sacroiliac joint (SIJ) fixation have the potential to reduce risk and improve patient outcomes, but evidence remains limited. This interim analysis presents initial findings from an ongoing prospective study evaluating the safety and efficacy of the Catamaran System.
METHODS: The primary endpoint of success at 6 months was defined as a ≥20 mm improvement in SIJ pain (Visual Analog Scale, VAS), no neurologic worsening, absence of device-related serious adverse events (SAEs), and no surgical reintervention. Secondary endpoints included 6 month evaluation of the Oswestry Disability Index (ODI), patient satisfaction, and 12 month radiographic CT fusion, performed by an indpendent radiologist.
RESULTS: Thirty-three consecutive patients (mean age: 58.9 years; %-females: 76%; Body Mass Index: 30.5) were treated across six U.S. clinical sites. At the primary endpoint of 6 months, 80% of patients met the criteria for success, with no device-related SAEs and no surgical reintervention reported. VASSIJ-Pain significantly decreased from preoperative levels (mean: 80.9 mm) to 6 months postoperatively (31.1 mm; p < 0.001). Mean ODI scores also showed a significant improvement from preoperative values (51.9%) to 6 months postoperatively (29.6%, p < 0.01). Patients reported high satisfaction rates throughout all follow-ups, with 93.3% of patients being satisfied at 6 months.
CONCLUSION: In patients diagnosed with chronic SIJ pain, minimally invasive inferior-posterior delivery of the Catamaran implant was safe and effective in relieving pain and reducing disability.
Participants rolling over from studies 209668, 209348, 212602, 202009, 219288, and 217023 who entered the parent study on stable NA therapy and remained on NA therapy for the duration of the treatment and follow-up periods in the parent study will be included in this arm. NA cessation will occur at 3 months in 206882 for eligible and willing participants. Participants will be followed up for 33 months. Participants rolling over from studies 209668 and 209348 who stopped NA treatment and are maintaining either FC or a partial response at Month 33, and remaining off NA treatment, will be eligible to be followed up for an additional 2 years. No study treatment will be administered in this study.
Myelodysplastic syndromes (MDS) is a highly heterogeneous myeloid neoplastic disease, which needs personalized evaluation and therapy. To analyze the features and significance of gene mutations for MDS patients with normal karyotype (NK) at diagnosis, targeted sequencing was conducted on 616 MDS patients with NK, alongside 457 MDS cases with abnormal karyotype (AK). The results showed that the incidence of somatic mutation reached 70.3% and 83.8% in the NK and AK group, respectively. Initial mutation including ASXL1, DNMT3A and TET2 were common in NK group, which is the same as AK group. Some karyotype-associated gene mutations, such as TP53 and U2AF1, were relatively rare in NK group. Moreover, 34 out of 91 samples who progressed to acute myeloid leukemia (AML) underwent repeat sequencing during follow-up. 25 cases were checked out with newly emerged mutations. The AML-associated genetic alterations mainly involved with active signaling and transcription factors. In patients with NK, serial targeted sequencing was employed for minimal residual disease (MRD) monitoring, indicating the efficacy and relapse of the patients. In summary, MDS with NK showed distinct mutation features from those with AK. High-frequency gene mutations together with the mutational evolution suggested the diagnostic and monitoring significance of next generation sequencing for NK-MDS.
This is a randomized, double blind placebo-controlled trial to examine the role of Relapse Prevention (RP) and Contingency Management (CMP) combined with Naltrexone (NTX) for the treatment of cocaine-alcohol dependence. Patients will be randomly assigned to NTX (100mg/d) or placebo combined with one of two psychotherapy conditions (RP or RP +CMP). Following a standardized consent and intake procedure patients will participate in a 12-week trial with thrice weekly visits. Manual-guided RP therapy will be delivered in weekly 60-minute individual sessions. CMP will be based on cocaine-negative urine screens and negative breath alcohol tests. Follow-up assessments will be conducted at 3 and 6 months after treatment.